NCT03991494View on ClinicalTrials.gov

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 29, 2019

Primary Completion Date

October 21, 2019

Study Completion Date

August 5, 2020

Conditions
Advanced Solid Tumors
Interventions
DRUG

[14C]-pamiparib

During the treatment phase, pamiparib 60 mg administered orally twice daily

Trial Locations (2)

CH63 4JY

The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington

Unknown

Royal Liverpool University Hospital Clinical Research Unit, Liverpool

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT03991494 - Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer | Biotech Hunter | Biotech Hunter